Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

類似資料

• Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
  著者:: Camerini, Andrea, 等
  出版事項: (2011)
• Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
  著者:: Valsuani, Chiara, 等
  出版事項: (2009)
• Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
  著者:: Camerini, Andrea, 等
  出版事項: (2015)
• Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
  著者:: Canale, Maria Laura, 等
  出版事項: (2020)
• Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
  著者:: Vinod, B S, 等
  出版事項: (2015)